Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ENGN

enGene Holdings Inc

Dec 13 • 04:00PM ET

6.08

Dollar change -0.51
Percentage change -7.74	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT QURE SRPT SGMO VYGR ADVM ADAP BNTC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.36	Insider Own	55.16%	Shs Outstand	44.22M	Perf Week	-29.71%
Market Cap	285.95M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	4.19%	Shs Float	22.86M	Perf Month	-25.12%
Income	-130.43M	PEG	-	EPS next Q	-0.40	Inst Own	30.92%	Short Float	3.36%	Perf Quarter	-10.46%
Sales	0.00M	P/S	-	EPS this Y	99.00%	Inst Trans	-6.24%	Short Ratio	3.92	Perf Half Y	-32.44%
Book/sh	5.21	P/B	1.17	EPS next Y	-11.77%	ROA	-94.04%	Short Interest	0.77M	Perf Year	-12.52%
Cash/sh	5.48	P/C	1.11	EPS next 5Y	-	ROE	-103.02%	52W Range	4.42 - 18.40	Perf YTD	-34.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.47%	52W High	-66.96%	Beta	-0.74
Dividend TTM	-	Quick Ratio	19.52	Sales past 5Y	0.00%	Gross Margin	-	52W Low	37.56%	ATR (14)	0.70
Dividend Ex-Date	Aug 03, 2015	Current Ratio	19.52	EPS Y/Y TTM	-103111.54%	Oper. Margin	-	RSI (14)	26.04	Volatility	12.50% 8.72%
Employees	33	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	27.62
Option/Short	No / Yes	LT Debt/Eq	0.10	EPS Q/Q	-544.47%	Payout	-	Rel Volume	4.92	Prev Close	6.59
Sales Surprise	-	EPS Surprise	14.73%	Sales Q/Q	-	Earnings	Sep 10 AMC	Avg Volume	195.93K	Price	6.08
SMA20	-23.45%	SMA50	-25.67%	SMA200	-40.74%	Trades		Volume	964,372	Change	-7.74%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-24	Initiated	Raymond James	Outperform	$23
Nov-18-24	Initiated	JMP Securities	Mkt Outperform	$18
Aug-28-24	Initiated	Oppenheimer	Outperform	$30
Apr-22-24	Initiated	Wells Fargo	Overweight	$30
Apr-15-24	Initiated	Guggenheim	Buy	$34
Mar-28-24	Initiated	UBS	Buy	$37
Mar-08-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	Leerink Partners	Outperform	$31

Nov-25-24 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire) +7.94%
Nov-05-24 08:00AM	enGene to Participate in Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Oct-25-24 08:00AM	enGene Announces $60 Million Private Placement Financing (Business Wire)
Oct-22-24 04:05PM	enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.93%
Oct-21-24 08:45AM	enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer (Business Wire) +8.98%
04:05PM	Loading…
Oct-01-24 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 06:30AM	Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort (Business Wire) -12.00%
Sep-14-24 10:08PM	enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now (Insider Monkey)
Sep-10-24 04:33PM	enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Aug-28-24 04:05PM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Jul-24-24 04:05PM	enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:30AM	enGene Announces Appointment of Ron Cooper as Chief Executive Officer (Business Wire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jun-14-24 07:01AM	enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire) -10.00%
May-29-24 07:30AM	enGene to Present at the Jefferies Global Healthcare Conference (Business Wire)
04:05PM	Loading…
May-15-24 04:05PM	enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors (Business Wire)
May-02-24 04:05PM	enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting (PR Newswire)
Apr-09-24 08:56AM	/C O R R E C T I O N -- enGene Inc./ (PR Newswire)
08:00AM	engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development (PR Newswire)
Mar-11-24 05:16PM	enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress (PR Newswire)
Mar-05-24 07:00AM	enGene To Present at the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-14-24 06:50AM	enGene Announces Oversubscribed $200 Million Private Placement Financing (PR Newswire) +116.54%
06:45AM	enGene Announces Leadership Succession Plan (PR Newswire)
Jan-30-24 07:00AM	enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary (PR Newswire) -7.11%
Jan-29-24 07:00AM	enGene Reports Full Year 2023 Financial Results and Recent Operational Progress (PR Newswire)
Dec-22-23 05:00PM	enGene Announces Expanded $50 Million Debt Facility with Hercules Capital (PR Newswire)
Dec-19-23 07:00AM	enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors (PR Newswire) +6.10%
Nov-29-23 07:00AM	enGene Appoints Ryan Daws as Chief Financial Officer (PR Newswire) -11.14%
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) +5.36%
Nov-02-23 07:00AM	Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company (ACCESSWIRE) -5.00%
07:30AM	Loading…
Nov-01-23 07:30AM	enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company (PR Newswire) -7.81%

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Forbion Growth Opportunities F	10% Owner	Oct 30 '24	Buy	8.90	561,797	4,999,993	3,032,430	Nov 01 04:15 PM
Forbion Growth Opportunities F	10% Owner	Sep 30 '24	Buy	6.34	341,332	2,163,362	2,400,791	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Sep 27 '24	Buy	5.97	41,639	248,699	2,059,459	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 01 '24	Buy	6.44	35,279	227,158	2,436,070	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Dec 29 '23	Buy	9.06	10,020	90,771	2,017,820	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 07 '24	Buy	6.55	11,844	77,531	2,469,833	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 02 '24	Buy	6.37	10,153	64,697	2,446,223	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 04 '24	Buy	6.54	5,997	39,242	2,457,989	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Dec 28 '23	Buy	7.69	5,050	38,827	2,007,800	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 03 '24	Buy	6.48	5,769	37,397	2,451,992	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Dec 27 '23	Buy	7.17	2,750	19,711	2,002,750	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 08 '24	Buy	6.60	800	5,278	2,470,633	Oct 18 04:15 PM
Cooper Ronald Harold Wilfred	Chief Executive Officer	Sep 27 '24	Buy	5.70	10,000	57,000	10,000	Oct 01 08:02 AM
Glickman Richard M	Director	May 28 '24	Option Exercise	0.89	120	107	24,675	May 29 06:12 PM
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 22 '24	Sale	15.00	47,854	717,810	3,036,153	Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 18 '24	Sale	15.01	4,575	68,671	3,084,107	Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 19 '24	Sale	15.00	100	1,500	3,084,007	Apr 22 05:22 PM
CHEUNG ANTHONY TZEYEW	Chief Technology Officer	Mar 18 '24	Option Exercise	0.89	52,940	47,117	102,873	Mar 20 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENGN

enGene Holdings Inc

Upgrade your FINVIZ experience